
Cerenome, Inc. (CNSY) has disclosed a new risk, in the Debt & Financing category. Cerenome, Inc. faces uncertainty regarding access to the remaining capital under its September 4, 2026 securities
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| CNSY | Cerenome | 0.95 | -11.84 | -92.57% |
| Name | Price | % Change | |
|---|---|---|---|
| $0.95 | -92.57% |

Cerenome, Inc. (CNSY) has disclosed a new risk, in the Debt & Financing category. Cerenome, Inc. faces uncertainty regarding access to the remaining capital under its September 4, 2026 securities

Cerenome, Inc. (CNSY) is scheduled to report 3rd quarter earnings on 11/16/2026. Regarding Q3 estimates, Wall Street analysts expect Cerenome, Inc. to post earnings of -$0.95 per share. Revenue expectations

Reports Q3 revenue $722,000, consensus $750,000. “Recognition of our first quarter of CNSide diagnostic revenue and commercial payments beginning in October is a tremendous landmark,” said Marc Hedrick, M.D., Cerenome’s

Cerenome (CNSY) announced the appointment of Ron Andrews as chief business officer, a newly created position. Andrews will continue to serve on the company’s board of directors. In his new

Cerenome (CNSY) announced that it has completed enrollment in the Phase 2 ReSPECT-GBM study. This multicenter, open-label trial is evaluating a single administration of Reyobiq, the company’s lead investigational radiotherapeutic,

Cerenome (CNSY) announced that new preclinical data presented at the 16th Biennial Rivkin Ovarian Cancer Research Symposium illustrate the emerging immunomodulatory properties of REYOBIQ, its lead investigational targeted radiotherapeutic. In

Cerenome, Inc. (CNSY) is scheduled to report 3rd quarter earnings on 10/15/2026. Regarding Q3 estimates, Wall Street analysts expect Cerenome, Inc. to post earnings of -$1.05 per share. Revenue expectations

An update from Cerenome ( ($CNSY) ) is now available. On September 30, 2026, Cerenome updated its corporate presentation for investors and analysts, outlining its positioning in CNS oncology and

Lake Street lowered the firm’s price target on Cerenome (CNSY) to $31 from $50 and keeps a Buy rating on the shares. The firm’s revised price target reflects updated CNSide

Cerenome (CNSY) received three AI model reiterations at higher scores after the company secured new financing that extends its cash runway. While the stock remains in a clear downtrend and
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.